+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

China Radiopharmaceuticals Market By Radioisotope, By Application, By Type, By End User: Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 90 Pages
  • May 2023
  • Region: China
  • Allied Market Research
  • ID: 5916169
The radiopharmaceuticals market has actually expanded substantially over the past years with the surge in the incidence of cancer cells, cardiovascular diseases, as well as other conditions worldwide. In terms of region, the worldwide market is generally dominated by Europe, Asia Pacific, as well as North America. China is expected to end up being the biggest radiopharmaceuticals market in the near future, due to the establishing health care facilities, population growth, increase in disposable earnings, rising occurrence of cancer cells, as well as improvements in nanotechnology.

Radioisotopes are the main elements of radiopharmaceuticals as well as are creating rapidly in nations such as China, India, as well as Japan. These radioisotopes are used for various medical applications, such as cancer therapy, medical diagnosis of cardiology, neurological, and also various other problems. They are majorly created by cyclotrons as well as various other technologies. In the diagnostic applications, the most frequently utilized radioisotopes are technetium 99m, fluorine 18, iodine I, and gallium 68.

Radiopharmaceuticals are made use of for both analysis as well as healing applications. The analysis radiopharmaceuticals are utilized for imaging, while the therapeutic radiopharmaceuticals are made use of to provide radiation therapy to certain websites in the body to ruin cancer cells. The major end-users in the radiopharmaceuticals market are healthcare facilities and also facilities, medical imaging facilities, research centers as well as labs, and also various other end-users.

The significant chauffeurs for the growth of the China radiopharmaceuticals market are raising frequency of cancers, neurological problems, enhancing healthcare infrastructure, and increase in non reusable revenues. The expanding senior citizen populace will certainly also fuel the marketplace growth, as senior individuals are a lot more susceptible to conditions than more youthful people. The government initiatives such as "Healthy China" started by the Chinese Government, additionally drive the marketplace development.

The technical developments in the radioisotope technology and also the expanding research and development tasks of numerous drugs, also enhance the market development. The growing demand for even more exact diagnostic devices for cancer and various other conditions, boosting demand for radiopharmaceuticals, as well as increasing concentrate on lowering healthcare expenses additionally drives the market growth.

The high price of radiopharmaceuticals and strict federal government policies are some of the significant restraints in the development of the China Radiopharmaceuticals Market. The radioisotope innovation entails high price as well as requires skilled labors, which has actually presented a major challenge in the marketplace growth. The shortage of competent personnel associated with the production as well as storage space of radiopharmaceuticals, also limits the marketplace development.

The climbing understanding amongst the health care specialists concerning profitable opportunity in the radiopharmaceuticals market gives enormous possibility for growth on the market. The development of mobile radiopharmaceuticals production innovation and also enhancing need for nuclear medicine, will develop extra opportunities in the radiopharmaceuticals market. The federal government initiatives to create infrastructure and rise financing for the radiopharmaceuticals market, additionally offers an excellent opportunity to the vendors in the radiopharmaceuticals market. The climbing need of radiopharmaceuticals in arising markets such as India, and Thailand gives numerous chances for the suppliers also. Additionally, the development in R & D activities aimed at boosting the top quality of radiopharmaceuticals, will open new opportunities for the vendors.

The future patterns in the China radiopharmaceuticals market consist of potential growth in the nuclear medicine applications, as it makes use of radiopharmaceuticals to deal with as well as photo illness affecting human health and wellness. The development of nanotechnology in radiopharmaceuticals is additionally expected to be an instrumental factor in the growth of the market. The raising use radiopharmaceuticals in the detection and therapy of cardiovascular diseases, neurological diseases, and also cancer will certainly also form the growth of the radiopharmaceuticals market. The access of brand-new gamers is enhancing the competition in the radiopharmaceuticals market, bring about the development of affordable remedies and boosted solutions. This pattern will positively affect the marketplace growth, as it offers far better access to radiopharmaceuticals, especially in the establishing economic climates.

The China radiopharmaceuticals market is fractional on the basis of radioisotopes used such as technetium 99m, fluorine 18, iodine I, gallium 68, and others. Technetium 99m is one of the most frequently used radioisotope, adhered to by fluorine 18 and also iodine I. It is made use of for the diagnosis as well as treatment of brain conditions, cancers cells, as well as other health problems. Gallium 68 is made use of for diagnosing prostate cancer and metastatic cancer cells, and for radiotherapy in radioactive therapy.

On the basis of application, the market is classified into cancer, cardiology and others. Due to raising cancer prevalence, soaring demand for precise diagnosis and increase in medical imaging, the cancer sector was the market's largest revenue contributor in 2022.

On the basis of type, the market is divided into therapeutic and dignostics. Due to rising need for precise diagnosis and a growth in PET imaging, the diagnostic segment contributed the most revenue to the market in 2022. Due to an increase in R&D activities for therapeutic radiopharmaceuticals and an increase in cancer incidence, the therapeutic segment is anticipated to grow at the quickest rate during the forecast period.

The market is divided into hospital and clinics, medical imaging centers and others based on the end users.The market was dominated by the hospitals and clinics segment in 2022, and this trend is anticipated to continue during the forecast period as hospitals implement more diagnostic techniques.

Key Benefits For Stakeholders

  • Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
  • Analyze the key strategies adopted by major market players in China radiopharmaceuticals market.
  • Assess and rank the top factors that are expected to affect the growth of China radiopharmaceuticals market.
  • Top Player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the China radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
  • Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)
  • SWOT Analysis

Key Market Segments

By Type

  • Diagnostic
  • Therapeutic

By End User

  • Hospitals and clinics
  • Medical Imaging centers
  • Others

By Radioisotope

  • Fluorine 18
  • Iodine I
  • Gallium 68
  • Others
  • Technetium 99m

By Application

  • Cancer
  • Cardiology
  • Others
  • Key Market Players
  • IBA Molecular (Belgium)
  • AECI Nuclear Products (South Africa)
  • Institute of Radiopharmaceuticals (China)
  • Beijing Beigene Molecular Probes Co Ltd (China)
  • Sinopharm Pharmaceuticals (China)
  • Shanghai Institute of Materia Medica (China)
  • Guangzhou Yeed Medical Technology Co Ltd (China)
  • Shanghai Pharmaceutical Group Co Ltd (China)
  • CSPC Pharmaceutical Group (China)
  • Jubilant Biosys (India)

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CHINA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: CHINA RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. IBA Molecular (Belgium)
9.2. AECI Nuclear Products (South Africa)
9.3. Institute of Radiopharmaceuticals (China)
9.4. Beijing Beigene Molecular Probes Co Ltd (China)
9.5. Sinopharm Pharmaceuticals (China)
9.6. Shanghai Institute of Materia Medica (China)
9.7. Guangzhou Yeed Medical Technology Co Ltd (China)
9.8. Shanghai Pharmaceutical Group Co Ltd (China)
9.9. CSPC Pharmaceutical Group (China)
9.10. Jubilant Biosys (India)
List of Tables
Table 01. China Radiopharmaceuticals Market, by Radioisotope, 2022-2032 ($ Million)
Table 02. China Radiopharmaceuticals Market, by Application, 2022-2032 ($ Million)
Table 03. China Radiopharmaceuticals Market, by Type, 2022-2032 ($ Million)
Table 04. China Radiopharmaceuticals Market, by End-user, 2022-2032 ($ Million)
Table 05. Iba Molecular (Belgium): Key Executives
Table 06. Iba Molecular (Belgium): Company Snapshot
Table 07. Iba Molecular (Belgium): Operating Segments
Table 08. Iba Molecular (Belgium): Product Portfolio
Table 09. Iba Molecular (Belgium): Key Stratergies
Table 10. Aeci Nuclear Products (South Africa): Key Executives
Table 11. Aeci Nuclear Products (South Africa): Company Snapshot
Table 12. Aeci Nuclear Products (South Africa): Operating Segments
Table 13. Aeci Nuclear Products (South Africa): Product Portfolio
Table 14. Aeci Nuclear Products (South Africa): Key Stratergies
Table 15. Institute of Radiopharmaceuticals (China): Key Executives
Table 16. Institute of Radiopharmaceuticals (China): Company Snapshot
Table 17. Institute of Radiopharmaceuticals (China): Operating Segments
Table 18. Institute of Radiopharmaceuticals (China): Product Portfolio
Table 19. Institute of Radiopharmaceuticals (China): Key Stratergies
Table 20. Beijing Beigene Molecular Probes Co Ltd (China): Key Executives
Table 21. Beijing Beigene Molecular Probes Co Ltd (China): Company Snapshot
Table 22. Beijing Beigene Molecular Probes Co Ltd (China): Operating Segments
Table 23. Beijing Beigene Molecular Probes Co Ltd (China): Product Portfolio
Table 24. Beijing Beigene Molecular Probes Co Ltd (China): Key Stratergies
Table 25. Sinopharm Pharmaceuticals (China): Key Executives
Table 26. Sinopharm Pharmaceuticals (China): Company Snapshot
Table 27. Sinopharm Pharmaceuticals (China): Operating Segments
Table 28. Sinopharm Pharmaceuticals (China): Product Portfolio
Table 29. Sinopharm Pharmaceuticals (China): Key Stratergies
Table 30. Shanghai Institute of Materia Medica (China): Key Executives
Table 31. Shanghai Institute of Materia Medica (China): Company Snapshot
Table 32. Shanghai Institute of Materia Medica (China): Operating Segments
Table 33. Shanghai Institute of Materia Medica (China): Product Portfolio
Table 34. Shanghai Institute of Materia Medica (China): Key Stratergies
Table 35. Guangzhou Yeed Medical Technology Co Ltd (China): Key Executives
Table 36. Guangzhou Yeed Medical Technology Co Ltd (China): Company Snapshot
Table 37. Guangzhou Yeed Medical Technology Co Ltd (China): Operating Segments
Table 38. Guangzhou Yeed Medical Technology Co Ltd (China): Product Portfolio
Table 39. Guangzhou Yeed Medical Technology Co Ltd (China): Key Stratergies
Table 40. Shanghai Pharmaceutical Group Co Ltd (China): Key Executives
Table 41. Shanghai Pharmaceutical Group Co Ltd (China): Company Snapshot
Table 42. Shanghai Pharmaceutical Group Co Ltd (China): Operating Segments
Table 43. Shanghai Pharmaceutical Group Co Ltd (China): Product Portfolio
Table 44. Shanghai Pharmaceutical Group Co Ltd (China): Key Stratergies
Table 45. Cspc Pharmaceutical Group (China): Key Executives
Table 46. Cspc Pharmaceutical Group (China): Company Snapshot
Table 47. Cspc Pharmaceutical Group (China): Operating Segments
Table 48. Cspc Pharmaceutical Group (China): Product Portfolio
Table 49. Cspc Pharmaceutical Group (China): Key Stratergies
Table 50. Jubilant Biosys (India): Key Executives
Table 51. Jubilant Biosys (India): Company Snapshot
Table 52. Jubilant Biosys (India): Operating Segments
Table 53. Jubilant Biosys (India): Product Portfolio
Table 54. Jubilant Biosys (India): Key Stratergies
List of Figures
Figure 01. China Radiopharmaceuticals Market, 2022-2032
Figure 02. Segmentation of China Radiopharmaceuticals Market, 2022-2032
Figure 03. Top Investment Pockets in China Radiopharmaceuticals Market (2023-2032)
Figure 04. Porter's Five - 1
Figure 05. Porter's Five - 2
Figure 06. Porter's Five - 3
Figure 07. Porter's Five - 4
Figure 08. Porter's Five - 5
Figure 09. Drivers, Restraints and Opportunities: China Radiopharmaceuticals Market
Figure 10. China Radiopharmaceuticals Market,By Radioisotope, 2022 ($ Million)
Figure 11. China Radiopharmaceuticals Market,By Application, 2022 ($ Million)
Figure 12. China Radiopharmaceuticals Market,By Type, 2022 ($ Million)
Figure 13. China Radiopharmaceuticals Market,By End-user, 2022 ($ Million)
Figure 14. Top Winning Strategies, by Year
Figure 15. Top Winning Strategies, by Development
Figure 16. Top Winning Strategies, by Company
Figure 17. Product Mapping of Top 10 Players
Figure 18. Competitive Dashboard
Figure 19. Competitive Heatmap: China Radiopharmaceuticals Market
Figure 20. Top Player Positioning, 2022
Figure 21. Iba Molecular (Belgium): Net Sales, 2020-2022* ($ Million)
Figure 22. Iba Molecular (Belgium): Revenue Share, by Segment, 2022 (%)
Figure 23. Iba Molecular (Belgium): Revenue Share, by Geography, 2022 (%)
Figure 24. Aeci Nuclear Products (South Africa): Net Sales, 2020-2022* ($ Million)
Figure 25. Aeci Nuclear Products (South Africa): Revenue Share, by Segment, 2022 (%)
Figure 26. Aeci Nuclear Products (South Africa): Revenue Share, by Geography, 2022 (%)
Figure 27. Institute of Radiopharmaceuticals (China): Net Sales, 2020-2022* ($ Million)
Figure 28. Institute of Radiopharmaceuticals (China): Revenue Share, by Segment, 2022 (%)
Figure 29. Institute of Radiopharmaceuticals (China): Revenue Share, by Geography, 2022 (%)
Figure 30. Beijing Beigene Molecular Probes Co Ltd (China): Net Sales, 2020-2022* ($ Million)
Figure 31. Beijing Beigene Molecular Probes Co Ltd (China): Revenue Share, by Segment, 2022 (%)
Figure 32. Beijing Beigene Molecular Probes Co Ltd (China): Revenue Share, by Geography, 2022 (%)
Figure 33. Sinopharm Pharmaceuticals (China): Net Sales, 2020-2022* ($ Million)
Figure 34. Sinopharm Pharmaceuticals (China): Revenue Share, by Segment, 2022 (%)
Figure 35. Sinopharm Pharmaceuticals (China): Revenue Share, by Geography, 2022 (%)
Figure 36. Shanghai Institute of Materia Medica (China): Net Sales, 2020-2022* ($ Million)
Figure 37. Shanghai Institute of Materia Medica (China): Revenue Share, by Segment, 2022 (%)
Figure 38. Shanghai Institute of Materia Medica (China): Revenue Share, by Geography, 2022 (%)
Figure 39. Guangzhou Yeed Medical Technology Co Ltd (China): Net Sales, 2020-2022* ($ Million)
Figure 40. Guangzhou Yeed Medical Technology Co Ltd (China): Revenue Share, by Segment, 2022 (%)
Figure 41. Guangzhou Yeed Medical Technology Co Ltd (China): Revenue Share, by Geography, 2022 (%)
Figure 42. Shanghai Pharmaceutical Group Co Ltd (China): Net Sales, 2020-2022* ($ Million)
Figure 43. Shanghai Pharmaceutical Group Co Ltd (China): Revenue Share, by Segment, 2022 (%)
Figure 44. Shanghai Pharmaceutical Group Co Ltd (China): Revenue Share, by Geography, 2022 (%)
Figure 45. Cspc Pharmaceutical Group (China): Net Sales, 2020-2022* ($ Million)
Figure 46. Cspc Pharmaceutical Group (China): Revenue Share, by Segment, 2022 (%)
Figure 47. Cspc Pharmaceutical Group (China): Revenue Share, by Geography, 2022 (%)
Figure 48. Jubilant Biosys (India): Net Sales, 2020-2022* ($ Million)
Figure 49. Jubilant Biosys (India): Revenue Share, by Segment, 2022 (%)
Figure 50. Jubilant Biosys (India): Revenue Share, by Geography, 2022 (%)

Companies Mentioned

  • IBA Molecular (Belgium)
  • AECI Nuclear Products (South Africa)
  • Institute of Radiopharmaceuticals (China)
  • Beijing Beigene Molecular Probes Co Ltd (China)
  • Sinopharm Pharmaceuticals (China)
  • Shanghai Institute of Materia Medica (China)
  • Guangzhou Yeed Medical Technology Co Ltd (China)
  • Shanghai Pharmaceutical Group Co Ltd (China)
  • CSPC Pharmaceutical Group (China)
  • Jubilant Biosys (India)

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...